To evaluate the spectrum of and determine the risk factors for the development of liver toxicity (hepatopathy) after therapy with vincristine, dactinomycin, and cyclophosphamide (VAC) for rhabdomyosarcoma in children and adolescents.
Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Vol 22, Issue 10, p1894